Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rxsight Inc (NQ: RXST )

47.25 -2.18 (-4.41%)
Streaming Delayed Price Updated: 12:14 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rxsight Inc

< Previous 1 2 3 Next >
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
RxSight Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why RxSight (RXST) Shares Are Falling
RxSight shares are trading lower by 5.6% during Thursday's session. The company announced pricing of its $100 million proposed public offering of common stock. 
Via Benzinga
What 10 Analyst Ratings Have To Say About RxSight
Via Benzinga
Assessing RxSight: Insights From 8 Financial Analysts
Via Benzinga
Forecasting The Future: 9 Analyst Projections For RxSight
Via Benzinga
Do You Have Your Eye On Vision Care Stocks?
For investors seeking stable and growing opportunities, eye care stocks are an attractive option. 
Via Talk Markets
RXST Stock Earnings: RxSight Beats EPS, Beats Revenue for Q1 2024
RXST stock results show that RxSight beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Chart Of The Day: RxSight - Cashing In On Cataracts
Earnings are estimated to increase 33.30% this year, increase an additional 26.60% next year and continue to compound at an annual rate of 19.00% for the next 5 years 
Via Talk Markets
Recap: RxSight Q4 Earnings
Via Benzinga
Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky." 
Via Benzinga
Breaking Down RxSight: 5 Analysts Share Their Views
Via Benzinga
Analyst Expectations for RxSight's Future
Via Benzinga
RxSight: Q3 Earnings Insights
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
RxSight's Earnings Outlook
Via Benzinga
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
Via Benzinga
The Analyst Landscape: 8 Takes On RxSight
Via Benzinga
Where RxSight Stands With Analysts
Via Benzinga
3 Stocks to Buy BEFORE They Become Household Names
The best way to find 100 baggers is to invest in undiscovered stock gems that have yet to become household names. 
Via InvestorPlace
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
RxSight's Earnings: A Preview
Via Benzinga
The Latest Analyst Ratings for RxSight
Via Benzinga
Analyst Expectations for RxSight's Future
Via Benzinga
Looking Into RxSight's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+
Needham analyst David Saxon reiterated a Buy rating on RxSight, Inc. (NASDAQ: RXST),  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.